GSK223559 Ph I/II study of GSK5733584 in combo with anti-cancer therapies for adv solid tumors - Clinical Trial

What is the Purpose of this Study?

This study tests a new cancer medicine. It has 3 parts:

- Screening (up to 28 days): You'll get tests like heart checks, scans, and blood work.

- Treatment: You'll visit the clinic every 3 weeks to get the study drug. There are different groups testing the drug with other treatments for cancers like ovarian and endometrial.

- Follow-Up: After treatment, you'll have check-ups at 30, 60, and 90 days, plus long-term follow-up with more tests.

What is the Condition Being Studied?

Adults with advanced solid tumors

Who Can Participate in the Study?

Who can join this study:

- Adults with solid tumors, which are a type of cancer.

- People with advanced or returning endometrial cancer who didn’t get better with regular treatments or can’t use them.

- People whose cancer got worse after at least one kind of treatment.

- People with advanced ovarian, fallopian tube, or peritoneal cancer confirmed by lab tests.

Age Group
Adults

What is Involved?

Doctors are doing a study to test a new cancer medicine called GSK5733584. They want to see if it's safe to use by itself or with other cancer medicines. The goal is to find out if it can help treat solid tumors (a kind of cancer) more effectively.

Study Details

Full Title
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Principal Investigator
Angeles Alvarez Secord, MD, MHSc
Gynecologic Oncologist
Protocol Number
IRB: PRO00118137
NCT: NCT06796907
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Support Duke Health research or honor a loved one with a tribute gift.